30 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
affairs at CSL Behring (from 2013 to 2019). Prior to that, she held leadership positions in regulatory affairs at companies formerly known as Shire … ), Genentech, Biogen, and Novartis, where she held a variety of leadership roles in the USA, Canada and globally. She has deep experience in product
6-K
EX-99.3
OBSVF
ObsEva SA
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
. ObsEva has partnered with Yuyuan BioScience Technology for the development and commercialization of nolasiban in China.
Leadership Transition
Dr … of expertise in women’s health, with increasing responsibilities in medical affairs strategy and leadership, as well as leading large clinical
6-K
EX-99.1
OBSVF
ObsEva SA
2 May 22
ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer
7:00am
and leadership, as well as leading large clinical development programs. She was previously Head of Medical and Clinical Affairs at Evofem Biosciences (NASDAQ
6-K
EX-99.1
OBSVF
ObsEva SA
7 Apr 22
ObsEva Annual General Meeting 2022
7:01am
she held a variety of leadership roles in the USA, Canada and globally. She has deep experience in product launches and has successfully brought
6-K
EX-99.1
OBSVF
ObsEva SA
10 Mar 22
ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update
7:11am
for the development and commercialization of nolasiban in China.
Leadership Expansion
Will Brown was appointed as Chief Financial Officer and member
6-K
EX-99.1
nn5orzfbz4pbx h4m
1 Feb 22
ObsEva Appoints Katja Buhrer as Chief Strategy Officer
6:05am
6-K
EX-99.2
tqkdm4y478 ayvdc
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
6-K
EX-99.2
7c574wmndm3o41 741
1 Jun 21
ObsEva SA Announces that Shareholders Approved all Board Proposals at its
6:30am
6-K
EX-99.1
n7f89m2m53gq
6 May 21
ObsEva appoints Clive Bertram as Chief Commercial Officer
6:05am
6-K
EX-99.1
7h7 6x25mpm9w
22 Apr 21
ObsEva Annual General Meeting 2021
6:31am
6-K
EX-99.1
vgzgy140mkm8xj4lg6np
31 Mar 21
Current report (foreign)
7:15am
6-K
EX-99.2
kzr5qslc11968hpk
17 Feb 21
ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference
6:04am
6-K
EX-99.1
7l0pze a1
10 Feb 21
ObsEva Provides Business Outlook for 2021
6:10am
6-K/A
EX-99.1
4q8xbxoj05kldwmrhbt
19 Jan 21
Current report (foreign) (amended)
6:25am
6-K
EX-99.1
cz784xwdawqm219kxix1
13 Jan 21
Current report (foreign)
4:00pm
6-K
EX-99.1
k91rf50a3vj6qn
4 Jan 21
ObsEva appoints David Renas as Chief Financial Officer
6:36am
6-K
EX-99.1
qzv5r2mfluk976 4o
9 Nov 20
ObsEva appoints Brian O’Callaghan as Chief Executive Officer
7:32am
6-K
EX-99.1
hv3lvjbwwvqrosp1k g4
1 Jul 20
ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA
6:15am